Drug Profile

VHB 937

Alternative Names: VHB-937

Latest Information Update: 24 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novartis Institutes for BioMedical Research
Class Monoclonal antibodies
Mechanism of Action TREM2 protein-stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Neurodegenerative disorders

Most Recent Events

21 Oct 2024 Novartis Pharmaceuticals plans a phase II trial for Amyotrophic lateral sclerosis in October 2024 (NCT06643481) (EudraCT-2024-512536-29-00)
19 Jun 2024 Preclinical trials in Neurodegenerative disorders in USA (unspecified route)
05 Apr 2024 Pharmacodynamics data from preclinical studies Neurodegenerative disorders presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com